The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.

Journal article

BACKGROUND: Lowering LDL cholesterol with statin regimens reduces the risk of myocardial infarction, ischaemic stroke, and the need for coronary revascularisation in people without kidney disease, but its effects in people with moderate-to-severe kidney disease are uncertain. The SHARP trial aimed to assess the efficacy and safety of the combination of simvastatin plus ezetimibe in such patients. METHODS: This randomised double-blind trial included 9270 patients with chronic kidney disease (3...

Expand abstract

Authors: Baigent, C; Landray, M; Reith, C; Emberson, J; Wheeler, D

• Publication status: Published
• Journal: Lancet
• Volume: 377
• Issue: 9784
• Pages: 2181-2192
• Publication date: 2011-06-01
• DOI: 10.1016/s0140-6736(11)60739-3
• EISSN: 1474-547X
• ISSN: 0140-6736
• Language: English
• Keywords: Survival Analysis; Renal Dialysis; Double-Blind Method; Humans; Severity of Illness Index; Treatment Outcome; Kidney Function Tests; Middle Aged; Aged; Drug Administration Schedule; Hypolipidemic Agents; Female; Drug Therapy, Combination; Confidence Intervals; Renal Insufficiency, Chronic; Cholesterol, LDL; Risk Assessment; Cardiovascular Diseases; Follow-Up Studies; Time Factors; Azetidines; Reference Values; Adult; Dose-Response Relationship, Drug; Simvastatin; Male; SHARP Investigators